- Home
- ZURA vs API Comparison
ZURA vs API Comparison
Compare ZURA & API Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZURA | API |
|---|---|---|
| Founded | 2022 | 2013 |
| Country | United States | United States |
| Employees | 40 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.4M | 406.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ZURA | API |
|---|---|---|
| Price | $5.12 | $4.01 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $13.00 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 425.7K |
| Earning Date | 05-14-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $13.46 |
| Revenue Next Year | N/A | $12.87 |
| P/E Ratio | ★ N/A | $92.30 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.26 | $3.14 |
| 52 Week High | $7.25 | $5.50 |
Technical Indicators
Market Signals| Indicator | ZURA | API |
|---|---|---|
| Relative Strength Index (RSI) | 59.46 | 44.98 |
| Support Level | $4.22 | $3.68 |
| Resistance Level | $5.82 | $4.01 |
| Average True Range (ATR) | 0.46 | 0.24 |
| MACD | 0.20 | -0.05 |
| Stochastic Oscillator | 66.40 | 31.28 |
Price Performance
Historical ComparisonAbout ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
About API Agora Inc.
Agora Inc provides real-time communication solutions. The company offers real-time video calling, voice calling, live audio and video streaming, recording, and real-time messaging. It serves the gaming, retail, and education industries. The company operates in the People's Republic of China and the United States of America and the majority of its revenue is derived from the People's Republic of China.